Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post-hoc analysis of the INITIATION study.

AIMS: To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla-300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration.

MATERIALS AND

METHODS

INITIATION was a 24-week, interventional, single-arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%-11.0%) received Gla-300. This post-hoc subgroup analysis assessed HbA1c change from baseline to week 24 (primary endpoint), other glycaemic endpoints, insulin dose, hypoglycaemia, body weight change, and treatment satisfaction (using the Diabetes Treatment Satisfaction Questionnaire [DTSQ]) by baseline age (<60 or ≥ 60 years) and disease duration (<5, ≥5 to <10 or ≥10 years in insulin-naïve participants, and <10, 10 to <15 or ≥15 years in those with prior basal insulin [BI]).

RESULTS

Of 568 participants, 191 were insulin-naïve and 377 had received prior BI. Over 24 weeks, Gla-300 improved HbA1c in all age and disease duration subgroups. The least squares mean HbA1c change ranged from -1.02% (-11.1 mmol/mol) to -1.55% (-16.9 mmol/mol) in insulin-naïve participants and from -0.55% (-6.0 mmol/mol) to -0.76% (-8.3 mmol/mol) in prior BI participants. HbA1c <7.0% (<53 mmol/mol) achievement (ranging from 19.5% to 40.7%), other glycaemic endpoints, insulin dose increases, body weight changes and DTSQ score improvements did not significantly differ across the majority of subgroups, and the hypoglycaemia risk remained low.

CONCLUSIONS

Gla-300 improved glycaemic control with a low risk of hypoglycaemia in Chinese people with T2D across all ages and disease durations, including older individuals and those with long-standing diabetes.